Paid Clinical Trials Vermont
Discover 205 paid clinical trials in Vermont. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
Sponsor:
University of Vermont Medical Center
Location:
Code:
NCT02389023
Conditions
Peripheral Artery Disease
Critical Limb Ischemia
Claudication
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
standard gauze dressing
Prevena Incision Management system
Phase 1 Trial of Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin for Stage IV Lung Cancer
Sponsor:
University of Vermont
Location:
Code:
NCT04311762
Conditions
Lung Cancer Metastatic
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
cisplatin
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Sponsor:
Hoffmann-La Roche
Location:
Code:
NCT06047080
Conditions
Large B-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Glofitamab
Polatuzumab vedotin
Rituximab
Cyclophosphamide
Doxorubicin
Testing the Combination of Inotuzumab Ozogamicin and Lower Dose Chemotherapy Compared to Usual Chemotherapy for Adults with B-Cell Acute Lymphoblastic Leukemia or B-Cell Lymphoblastic Lymphoma
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT05303792
Conditions
B Acute Lymphoblastic Leukemia
B Lymphoblastic Lymphoma
Eligibility Criteria
Sex: All
Age: 50+
Healthy Volunteers: Not accepted
Interventions
Cyclophosphamide
Vincristine
Dexamethasone
Inotuzumab Ozogamicin
Methotrexate
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Sponsor:
Alliance for Clinical Trials in Oncology
Location:
Code:
NCT04803201
Conditions
Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Follicular T-Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Cyclophosphamide
Doxorubicin
Vincristine
Prednisone
Etoposide
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Sponsor:
Medtronic Vascular
Location:
Code:
NCT05198674
Conditions
Hypertension
Vascular Diseases
Cardiovascular Diseases
Chronic Kidney Diseases
Diabetes Mellitus
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Renal Denervation (Symplicity Spyral™)
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG
Sponsor:
Icahn School of Medicine at Mount Sinai
Location:
Code:
NCT04045665
Conditions
Atrial Fibrillation
Stroke
Bleeding
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Antiplatelet-only strategy
Oral Anticoagulant plus background antiplatelet therapy
Product Surveillance Registry
Sponsor:
Medtronic
Location:
Code:
NCT01524276
Conditions
Cardiac Rhythm Disorders
Urological Disorders
Neurological Disorders
Cardiovascular Disorders
Digestive Disorders
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
Sponsor:
AstraZeneca
Location:
Code:
NCT06268873
Conditions
Chronic Kidney Disease and Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Baxdrostat/dapagliflozin
Dapagliflozin in combination with placebo
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Sponsor:
Dennis M. McNamara, MD, MS
Location:
Code:
NCT05180773
Conditions
Peripartum Cardiomyopathy, Postpartum
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Bromocriptine
Placebo
Guideline Directed Medical Therapy for Heart Failure (GDMT)
Rivaroxaban
Second Placebo